Skip to main content

Horizon Therapeutics Public Ltd Co

HZNPDelisted Oct 6, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001492426

Horizon Therapeutics Public Ltd Co was delisted on Oct 6, 2023; its insiders filed their last Form 4 on Oct 6, 2023; 483 institutions reported holding it in 13F filings for Q3 2023, worth $24.8B in total; Soros Fund Management was the only superinvestor holding it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
483
Q3 2023, −31 vs. previous quarter
13F value
$24.8B
Reported value at the end of Q3 2023
Superinvestors holding
1
At the end of Q3 2023

From SEC filings, in USD.

Revenue, FY2022
$3.63B
+12.5% year over year
Net income, FY2022
$521.5M
−2.4% year over year
Free cash flow, FY2022
$1.19B
+24.5% year over year
Revenue, Q2 FY2023
$945.0M
+7.8% year over year

Revenue flow, FY2022

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Superinvestors holding HZNP, Q3 2023

Go to the superinvestors tab

1 superinvestor reports holding Horizon Therapeutics Public Ltd Co on Form 13F. Percentages are the stock's share of each portfolio.

Soros Fund Management

George Soros

7.8%

Horizon Therapeutics Public Ltd Co's share of the portfolio

Shares
3,289,584
Value
$380.6M

Latest insider trades

See all insider trades

Open-market purchases and sales by Horizon Therapeutics Public Ltd Co insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 18, 2023 (view filing)Jan 171 dayPasternak AndyEVP, Chief Strategy OfficerSSale−27.1K$113.03−$3.07M−32.5%56.3K after
Jan 17, 2023 (view filing)Jan 134 daysCox AaronEVP, Chief Financial OfficerSSale−36.1K$113.17−$4.09M−99.2%277 after
Jan 12, 2023 (view filing)Jan 10-112 daysSherman Jeffrey WEVP and Chief Medical OfficerSSale−6.74K$113.08−$761.7K−15.7%36.2K after2 lots
Jan 6, 2023 (view filing)Jan 6Same daySherman Jeffrey WEVP and Chief Medical OfficerSSale−5.19K$113.29−$587.6K−9.5%49.3K after
Dec 14, 2022 (view filing)Dec 131 dayPasternak AndyEVP, Chief Strategy OfficerSSale−30.2K$112.61−$3.40M−47.0%34.0K after2 lots
Dec 13, 2022 (view filing)Dec 121 daySherman Jeffrey WEVP and Chief Medical OfficerSSale−28.4K$111.45−$3.16M−25.1%84.4K after2 lots
Aug 8, 2022 (view filing)Aug 44 daysClayton Sean M.EVP, General CounselPPurchase+745$66.67+$49.7KNew position745 after
Jul 29, 2022 (view filing)Jul 29Same dayPasternak AndyEVP and Chief Business OfficerSSale−4.85K$82.57−$400.5K−12.5%34.0K after2 lots
Jul 20, 2022 (view filing)Jul 19-201 dayThompson Elizabeth H.Z.EVP, Research & DevelopmentSSale−6.01K$85.00−$510.6K−46.3%6.97K after3 lots
Jul 11, 2022 (view filing)Jul 74 daysThompson Elizabeth H.Z.EVP, Research & DevelopmentSSale−82$85.01−$6.97K−0.6%13.0K after

Top 10 13F holders, Q3 2023

See all 483 holders

The largest institutional positions in Horizon Therapeutics Public Ltd Co at the end of Q3 2023; share changes are against Q2 2023.

Institutions holding HZNP in Q3 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Group Inc21,587,441$2.50B0.06%+42,917+0.2%Added
Pentwater Capital Management LP15,552,000$1.80B17.32%+2,825,100+22.2%Added
BlackRock Inc.14,871,176$1.72B0.05%−32,505−0.2%Reduced
HBK Investments L P7,978,967$923.1M20.48%+1,928,967+31.9%Added
UBS Oconnor LLC7,664,245$886.7M15.86%+3,332,978+77.0%Added
Norges Bank7,105,064$822.0M0.17%+1,547,758+27.9%Added
Avoro Capital Advisors LLC7,000,000$809.8M12.63%00.0%Unchanged
Farallon Capital Management, L.L.C.6,656,823$770.1M4.35%−265,000−3.8%Reduced
State Street Corp5,233,927$605.5M0.03%−40,125−0.8%Reduced
JPMorgan Chase & Co5,042,293$583.3M0.07%−448,947−8.2%Reduced

2 members of Congress reported 2 trades in Horizon Therapeutics Public Ltd Co since 2020. Newest filings:

  1. Greg Landsman

    House · OH · Aug 14, 2024

    Sell$1K-$15K

  2. Daniel S. Goldman

    House · NY · Feb 24, 2023

    Sell$15K-$50K